| アブストラクト | BACKGROUND: Acute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach. Eptifibatide, a glycoprotein IIb/IIIa receptor inhibitor (GPI), is primarily used to treat acute coronary syndrome (ACS) and non-venous thromboembolic pulmonary embolism, as well as for antiplatelet therapy in conditions such as ARDS and septic shock. With its increasing clinical application, understanding its safety profile in real-world settings is essential. METHODS: This study evaluated the clinical safety of Eptifibatide by analyzing all adverse event (AEs) reports in the FDA Adverse Event Reporting System (FAERS) where Eptifibatide was listed as the primary suspected drug since 2004. Analytical methods included the Bayesian Confidence Propagation Neural Network (BCPNN), the UK Medicines and Healthcare Products Regulatory Agency (MHRA) comprehensive standard method, the Multi-item Gamma Poisson Shrinker (MGPS), the Proportional Reporting Ratio (PRR), and the Reporting Odds Ratio (ROR). RESULTS: The study confirmed known adverse reactions of Eptifibatide, such as bleeding, intracranial hemorrhage, stroke, thrombocytopenia, allergic reactions, immunogenicity, and hypotension, which are also listed in the drug's prescribing information. Additionally, some previously unmentioned adverse reactions were identified, including acute myocardial infarction, cardiac arrest, nausea, hemorrhagic pancreatitis, chills, dyspnea, and vascular pseudoaneurysm. The study also highlighted the importance of early detection of adverse reactions to Eptifibatide. CONCLUSION: This research provides insights into both known and potential adverse reactions associated with Eptifibatide in real-world clinical use, offering additional safety information for clinicians when prescribing Eptifibatide for ARDS treatment. |
|---|
| ジャーナル名 | Frontiers in medicine |
|---|
| Pubmed追加日 | 2026/3/16 |
|---|
| 投稿者 | Zhang, Peng; Wang, Wenjing; Zhao, Ting; Wang, Guoping; Shang, Fanyong; Ji, Feng |
|---|
| 組織名 | Department of Pulmonary and Critical Care Medicine, Shandong Provincial Third;Hospital, Jinan, China.;Department of Infectious Diseases, Shandong Second Provincial General Hospital,;Jinan, China.;Department of Respiratory Medicine, Shandong Provincial Corps Hospital of the;Chinese People's Armed Police Force, Jinan, China.;Department of Internal Medicine, Lijin County Hospital of Traditional Chinese;Medicine, Dongying, China.;Department of General Surgery, Lijin County Hospital of Traditional Chinese;Department of Intensive Care Unit, Jinan Central Hospital East Campus, Jinan,;China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41836947/ |
|---|
